Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
J Neurol
    October 2026
  1. GILHUS NE, Melsom SC, Bugge C
    Healthcare costs and burden of myasthenia gravis for patients and society: a systematic review.
    J Neurol. 2026;273:648.
    >> Share

  2. MASUDA Y, Matsuda S, Okazaki A, Tsuge R, et al
    Clinical features and prognosis of EGPA-associated peripheral neuropathy: a multicentre REVEAL cohort study.
    J Neurol. 2026;273:641.
    >> Share

  3. PALAZZO L, Clarelli F, Giordano A, Ferre L, et al
    Incidence of Progression Independent of Relapse Activity (PIRA) under platform disease-modifying treatment in multiple sclerosis.
    J Neurol. 2026;273:640.
    >> Share

    September 2026
  4. KOREN TJ, Dugal J, Wang D, Beadnall H, et al
    Spinal cord imaging in multiple sclerosis: from diagnosis to disease progression.
    J Neurol. 2026;273:634.
    >> Share

  5. NICOLELLA V, Polito C, Criscuolo V, Varelli M, et al
    Evaluating the neurofilament light chain-derived gap between biological and chronological age in multiple sclerosis and controls.
    J Neurol. 2026;273:625.
    >> Share

  6. STAMENKOVIC M, Vukovic I, Milosevic E, Peric S, et al
    The role of leukocyte p38 MAP kinase in immune-mediated peripheral polyneuropathies: distinct modulation by intravenous immunoglobulins.
    J Neurol. 2026;273:627.
    >> Share

  7. HEDSTROM AK, Olsson T, Alfredsson L
    Family history of multiple sclerosis and long-term outcomes.
    J Neurol. 2026;273:622.
    >> Share

  8. GUO Q, Olsson T, Alfredsson L, Hedstrom AK, et al
    Leisure-time physical activity, sun exposure, and multiple sclerosis risk: a population-based case-control study.
    J Neurol. 2026;273:623.
    >> Share

  9. JAKIMOVSKI D, Weller J, Zivadinov R, Weinstock-Guttman B, et al
    VEP latency delays predicts MRI neurodegenerative outcomes in multiple sclerosis.
    J Neurol. 2026;273:621.
    >> Share

  10. D'HAESELEER M, Strijbis EMM, Cutter G, Della Faille L, et al
    Clinical trials in non-ambulatory people with progressive multiple sclerosis: can the nine hole peg test step up as primary outcome measure?
    J Neurol. 2026;273:608.
    >> Share

  11. PETZA E, Guerrieri S, Marino V, Gattuso I, et al
    Ocrelizumab-related organizing pneumonia in multiple sclerosis: insights from a case series and literature review.
    J Neurol. 2026;273:600.
    >> Share

  12. XIE Y, Wu S, Zhang Y, Ju C, et al
    Comparison of iron and myelin changes in U?fiber regions of relapsing-remitting multiple sclerosis and neuromyelitis optica spectrum disorders.
    J Neurol. 2026;273:596.
    >> Share

  13. MORI Y, Takekoshi A, Ono Y, Yoshikura N, et al
    Characteristics and prognostic factors of cognitive impairment in autoimmune glial fibrillary acidic protein astrocytopathy.
    J Neurol. 2026;273:586.
    >> Share

  14. MATTIESING RM, Gentile G, Battaglini M, De Stefano N, et al
    The predictive value of serum neurofilament light chain levels beyond MRI measures for clinical and radiological disease progression in the earliest stages of multiple sclerosis.
    J Neurol. 2026;273:584.
    >> Share

  15. ESPOSITO A, Corsaro L, Cave ID, Capasso F, et al
    Ofatumumab in multiple sclerosis: 2-year immune profiling and clinical correlates.
    J Neurol. 2026;273:579.
    >> Share

  16. GUO J, Wu J, Olsson T, Alfredsson L, et al
    Genetic modification of obesity-associated disability progression in multiple sclerosis.
    J Neurol. 2026;273:578.
    >> Share

  17. MIESENBERGER AS, Arlt FA, Koschutzke L, Gebert P, et al
    Autoantibodies targeting G protein-coupled receptors and clinical outcome after ischemic stroke (PROSCIS-B).
    J Neurol. 2026;273:581.
    >> Share

  18. MARINO V, Moiola L, Zanetta C, Rubin M, et al
    Ocrelizumab versus ofatumumab efficacy and safety after natalizumab discontinuation in multiple sclerosis: a retrospective real-world comparison.
    J Neurol. 2026;273:577.
    >> Share

  19. LINDROOS JLV, Gilhus NE, Brauner S, Bjork MH, et al
    Medication use trajectories in myasthenia gravis pregnancies: a population-based drug utilization study.
    J Neurol. 2026;273:572.
    >> Share

  20. HEBER ME, Li Y, Raymond DP, Li Y, et al
    A comparison study of thymectomy outcomes in young and older patients with non-thymomatous myasthenia gravis.
    J Neurol. 2026;273:566.
    >> Share

  21. MULLER T, Giles L, Hauquiert B, Gonze A, et al
    Severe invasive pneumococcal pneumonia following influenza A in a patient with multiple sclerosis treated with dimethyl fumarate: the importance of vaccination assessment and hematologic monitoring.
    J Neurol. 2026;273:571.
    >> Share

    August 2026
  22. PENG HH, Nhu NT, Hou WH
    Effectiveness of vestibular rehabilitation in patients with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2026;273:553.
    >> Share

  23. CRISCUOLO V, Nicolella V, Polito C, Sirica R, et al
    Real-world Roche Elecsys((R)) and Fujirebio Lumipulse((R)) inter-platform comparability and clinical validation of plasma neurofilament light chain in multiple sclerosis.
    J Neurol. 2026;273:546.
    >> Share

  24. DE MAURO A, Cortese R, Fadda G, De Stefano N, et al
    Central vein sign and paramagnetic rim lesions in pediatric-onset multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2026;273:540.
    >> Share

  25. JIANG M, Rubin M, Storelli L, Grosselle M, et al
    Subjective sleep disturbances are associated with reduced MRI-derived perivascular-space diffusivity in multiple sclerosis.
    J Neurol. 2026;273:538.
    >> Share

  26. GABELIC T, Tesija K, Sredanovic M, Adamec I, et al
    Persistent B-cell depletion after ublituximab for multiple sclerosis.
    J Neurol. 2026;273:536.
    >> Share

  27. FOURNET A, Munsch F, Koubiyr I, Vidal JP, et al
    Interthalamic adhesion alterations in multiple sclerosis: associations with thalamic damage and cognition.
    J Neurol. 2026;273:535.
    >> Share

  28. BROCHET B, Moreau T, Saubusse A, Charre-Morin J, et al
    Episodic memory deficits are associated with social cognitive impairments in multiple sclerosis.
    J Neurol. 2026;273:534.
    >> Share

  29. LU X, Dai H, Zhao L, Huang W, et al
    Time- and threshold-dependent cerebrospinal fluid protein elevation and albuminocytologic dissociation in Guillain-Barre syndrome: a systematic review and meta-analysis.
    J Neurol. 2026;273:527.
    >> Share

  30. XIAO L, Qin B, Guo Y, Zhang P, et al
    Gastrointestinal dysfunction associated with autoimmune glial fibrillary acidic protein astrocytopathy.
    J Neurol. 2026;273:521.
    >> Share

  31. CERDA-FUERTES N, Sankar S, Pless S, Stoessel M, et al
    Retinal layers prognosticate cognitive progression independent of relapse activity in multiple sclerosis.
    J Neurol. 2026;273:517.
    >> Share

  32. SREDANOVIC M, Hentzen C, Adamec I, Chesnel C, et al
    Gastrointestinal symptoms and disorders in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2026;273:515.
    >> Share

  33. RICIGLIANO VAG, Ciron J, Bourre B, Guennoc AM, et al
    French expert opinion on the long-term management of relapsing multiple sclerosis with cladribine tablets beyond year 4.
    J Neurol. 2026;273:507.
    >> Share

    July 2026
  34. ACHILLE M, Copetti M, Guerra T, Ferri C, et al
    Prognostic factors in paediatric-onset multiple sclerosis: a narrative review.
    J Neurol. 2026;273:495.
    >> Share

  35. WANG J, Wang X, Zhou Q, He L, et al
    Autoimmune encephalitis in eastern China over last decade: a multi-center retrospective study.
    J Neurol. 2026;273:485.
    >> Share

  36. GAIST TA, Nissen MS, Funch SSA, Blok-Andersen M, et al
    Fifteen years of autoimmune encephalitis in Denmark: incidence, epidemiology, and trends in treatment.
    J Neurol. 2026;273:488.
    >> Share

  37. CAI MT, Lai QL, Su SY, Fu YL, et al
    Real-world application of the conventional components of the 2024 McDonald diagnostic criteria for multiple sclerosis in China: a comparative study with the 2017 criteria.
    J Neurol. 2026;273:473.
    >> Share

  38. DUMEZ P, Le Marechal M, Benaiteau M, Buttard C, et al
    Sensitivity of the UT-Hopkins Score in 350 patients with antibody-mediated autoimmune encephalitis.
    J Neurol. 2026;273:470.
    >> Share

  39. AGUESSE C, Micoud E, Vukusic S, Venet F, et al
    External validation of KFLC index threshold for multiple sclerosis diagnosis in a French cohort.
    J Neurol. 2026;273:469.
    >> Share

  40. MORELLI L, Ricciardiello F, Furia A, Incensi A, et al
    Autoantibodies in small fiber neuropathy: frequency and clinical features associated with antibodies to the novel targets MX1 and DBNL.
    J Neurol. 2026;273:468.
    >> Share

  41. LIAMPAS I, Demiri S, Malataras G, Polyviou A, et al
    Very late-onset myasthenia gravis: a systematic review and meta-analysis of sex distribution, thymic pathology and autoantibodies.
    J Neurol. 2026;273:466.
    >> Share

  42. HERNANDEZ-LOPEZ V, Smith JB, Alsalek S, Scott JN Jr, et al
    Anti-NMDA receptor encephalitis outcomes in a population-based cohort.
    J Neurol. 2026;273:462.
    >> Share

  43. CHAUDHRY TS, Nathoo N, Coen BA, Chowdhury P, et al
    Clinical course of critical demyelinating lesion-associated progressive multiple sclerosis.
    J Neurol. 2026;273:456.
    >> Share

  44. MOURA FC
    Monocular pendular nystagmus following optic neuritis in multiple sclerosis: a case report and pathophysiological review.
    J Neurol. 2026;273:457.
    >> Share

  45. INOJOSA H, Masanneck L, Akgun K, Hagler R, et al
    From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis.
    J Neurol. 2026;273:454.
    >> Share

  46. FILIPPI M, Grimaldi LME, Brescia Morra V, Conte A, et al
    Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.
    J Neurol. 2026;273:452.
    >> Share

  47. KOKS F, Reubens F, van der Zee H, Briede JJ, et al
    The dual role of mTOR in multiple sclerosis pathophysiology: a systematic review.
    J Neurol. 2026;273:441.
    >> Share

  48. HU Y, Wen M, Wen L, Cheng R, et al
    Comorbid autoimmune disease in stiff-person syndrome spectrum disorder: a systematic review and meta-analysis.
    J Neurol. 2026;273:442.
    >> Share

  49. ARATAKE Y, Yoshinaga K, Ashida S, Fujii C, et al
    Beyond dissemination criteria: lesion-based longitudinal MRI of atypical demyelinating lesions at the boundary of multiple sclerosis.
    J Neurol. 2026;273:438.
    >> Share

    June 2026
  50. BOVE R, Langdon D, Maciejowski M, Jasinska E, et al
    Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study.
    J Neurol. 2026;273:434.
    >> Share

  51. CALISTRI V, Pezzella FR, Prosperini L
    Triple-crush mechanism in multiple sclerosis-associated trigeminal neuralgia.
    J Neurol. 2026;273:431.
    >> Share

  52. GANGEMI E, Piervincenzi C, Tommasin S, Ojha A, et al
    The relationship between cerebellar functional connectivity alterations and hand dexterity impairment in multiple sclerosis.
    J Neurol. 2026;273:425.
    >> Share

  53. VISSING J, Pease S, Scippa K, Gandhi K, et al
    Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study.
    J Neurol. 2026;273:423.
    >> Share

  54. MUNOZ-VENDRELL A, Arroyo-Pereiro P, Leon I, Bau L, et al
    Serum biomarkers remain stable after transitioning from intravenous to subcutaneous natalizumab in multiple sclerosis.
    J Neurol. 2026;273:412.
    >> Share

  55. FREITAS-HUHTAMAKI A, Kleebauer N, Gardner A, Lundberg J, et al
    Screening 1021 Swedish memory clinic visitors for autoantibody-mediated encephalitis.
    J Neurol. 2026;273:408.
    >> Share

  56. WILLEMS S, D'hooghe MB, Sastre-Garriga J, Pareto D, et al
    Spinal cord reserve is associated with multi-dimensional clinical resilience in multiple sclerosis.
    J Neurol. 2026;273:402.
    >> Share

  57. GUGER M, Enzinger C, Heschl B, Di Pauli F, et al
    The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.
    J Neurol. 2026;273:392.
    >> Share

  58. XING C, Li W, Tian R, Hu M, et al
    Efgartigimod as adjunctive therapy in refractory autoimmune glial fibrillary acidic protein astrocytopathy: a case series.
    J Neurol. 2026;273:385.
    >> Share

  59. FOTTINGER F, Krajnc N, Berek K, Nolte JP, et al
    Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosis.
    J Neurol. 2026;273:382.
    >> Share

  60. MA LL, Dai K, Ma XM, Liu YY, et al
    Clinical characteristics of late-onset adult autoimmune glial fibrillary acidic protein astrocytopathy: a retrospective cohort study.
    J Neurol. 2026;273:377.
    >> Share

  61. ESPOSITO F, Misra K, Doyle F, Clarelli F, et al
    Distinct age-related pattern of mitochondrial somatic mutations across multiple sclerosis phenotypes.
    J Neurol. 2026;273:374.
    >> Share

  62. REUTER E, Luerweg J, Katsimpoura M, Haselon J, et al
    Virtual reality-based oculography detects internuclear ophthalmoplegia in multiple sclerosis and other neurological disorders.
    J Neurol. 2026;273:372.
    >> Share

  63. BERGSLAND N, Burnham A, Dwyer MG, Bartnik A, et al
    Ultra-low-field MRI for bedside imaging of severe multiple sclerosis.
    J Neurol. 2026;273:364.
    >> Share

  64. TEDONE N, Preziosa P, Pagani E, Meani A, et al
    Structural MRI signature of late- versus adult-onset multiple sclerosis: a multiparametric study.
    J Neurol. 2026;273:360.
    >> Share

  65. HOWARD JF JR, Sacca F, Hoffmann S, Attarian S, et al
    Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double?blind, placebo?controlled, phase 3 trial (ADAPT).
    J Neurol. 2026;273:363.
    >> Share

  66. BET MDA, Helmlinger B, Broeders TAA, Hechenberger SMC, et al
    Functional connectivity dynamics of monoaminergic circuits related to fatigue in multiple sclerosis.
    J Neurol. 2026;273:354.
    >> Share

  67. HOF SN, Keytsman E, Fuchs TAN, Wessels MHJ, et al
    What if it is the eyes? The effect of eye movement disorders on cognitive testing in MS.
    J Neurol. 2026;273:355.
    >> Share

    May 2026
  68. PEGORINI C, Cattaneo D, Meotti M, Baglio F, et al
    Artificial intelligence for gait and balance in neurological disorders: a scoping review of clinical applications and technologies.
    J Neurol. 2026;273:346.
    >> Share

  69. MENG H, Qi Y, Zhang M, Wang X, et al
    (18)F-DPA714 PET in MRI-negative autoimmune encephalitis: a supportive approach to aiding neuroinflammation identification, disease severity correlation, and treatment response prediction.
    J Neurol. 2026;273:342.
    >> Share

  70. RUBIN M, Preziosa P, Margoni M, Storelli L, et al
    Cerebrovascular risk factors impact on brain atrophy and DTI-ALPS decrease in neuromyelitis optica spectrum disorder.
    J Neurol. 2026;273:338.
    >> Share

  71. SURCINELLI A, Panzera I, Piscaglia MG, Zagnoli S, et al
    Late-onset multiple sclerosis is associated with relapse-independent disability accrual: a propensity score-weighted recurrent-event study.
    J Neurol. 2026;273:332.
    >> Share

  72. ROMANO F, Valsasina P, Albergoni M, Amato MP, et al
    Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study.
    J Neurol. 2026;273:325.
    >> Share

  73. GUO J, Johansson E, Hillert J, Olsson T, et al
    Trajectories of processing speed in multiple sclerosis across disease-modifying therapies.
    J Neurol. 2026;273:324.
    >> Share

  74. PAN J, Yaguchi H, Kudo A, Fujii S, et al
    Nationwide screening identifies an expanded clinical spectrum of anti-KLHL11 antibody-associated neurologic disease in Japan.
    J Neurol. 2026;273:321.
    >> Share

  75. BERGAMASCHI R, Ferraro OE, Pisoni E, Fronza M, et al
    Correction: Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.
    J Neurol. 2026;273:319.
    >> Share

  76. ANDERSEN RK, Ankjaer P, Axelsen KH, Andersen LK, et al
    Prevalence and characteristics of patients with seronegative myasthenia gravis.
    J Neurol. 2026;273:308.
    >> Share

  77. DE JONG DJ, Molenaar PCG, Verhoef V, Novakova L, et al
    The practice effect of smartphone-derived cognitive processing speed assessments as a proxy of cognitive functioning in multiple sclerosis.
    J Neurol. 2026;273:305.
    >> Share

  78. MAGGI G, Altieri M, d'Ambrosio A, Risi M, et al
    Refining neuropsychological assessment strategies in multiple sclerosis: insights from long-term cognitive trajectories.
    J Neurol. 2026;273:304.
    >> Share

  79. FILIPPI M, D'Amico E, Brescia Morra V, Zanetta C, et al
    Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective cohort.
    J Neurol. 2026;273:302.
    >> Share

    April 2026
  80. TUOMAALA J, Saraste M, Smith E, Kuusi M, et al
    Association between post-COVID-19 neuropsychiatric symptoms and persistent glial activation in the limbic system: a TSPO PET study.
    J Neurol. 2026;273:298.
    >> Share

  81. PENNER IK, Maier T, Wiemer T, Leemhuis J, et al
    Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy.
    J Neurol. 2026;273:292.
    >> Share

  82. IND G, Hashmi Z, Ahuja S, Fayad T, et al
    Demyelinating disorders in women: epidemiology, immunology, and clinical implications across MS, NMOSD, and MOGAD.
    J Neurol. 2026;273:290.
    >> Share

  83. PASNOOR M, Miller-Wilson LA, Edwards Y, Copley-Merriman K, et al
    Burden of Disease in Myasthenia Gravis: A Targeted Literature Review.
    J Neurol. 2026;273:288.
    >> Share

  84. AVEDILLO-SALAS A, Martinez LB, Fanlo-Villacampa A, Vicente-Romero J, et al
    Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review.
    J Neurol. 2026;273:286.
    >> Share

  85. BROCHARD V, Lecler A, Januel E, Chaugne E, et al
    Optic chiasmal neuritis: clinical features, aetiologies, MRI patterns and prognosis in a real-world cohort.
    J Neurol. 2026;273:282.
    >> Share

  86. FUCHS TAN, Schoonheim MM, Strijbis EMM, Jelgerhuis JR, et al
    Predicting disease progression in multiple sclerosis with clinically accessible information and technology.
    J Neurol. 2026;273:281.
    >> Share

  87. RINALDI E, Puleo E, Di Maro A, Fusco R, et al
    Enhanced antibody detection via live cell-based assay among RIA negative myasthenia gravis patients: toward improved diagnosis and clinical correlates.
    J Neurol. 2026;273:277.
    >> Share

  88. SUSINNA C, Restuccia G, Triolo G, Marafioti G, et al
    Iron accumulation in multiple sclerosis and implications for cognitive and clinical progression: a systematic review of advanced neuroimaging studies.
    J Neurol. 2026;273:275.
    >> Share

  89. HEGEN H, Fottinger F, Walde J, Berek K, et al
    The role of age in choosing high-efficacy treatment for multiple sclerosis: an Austrian MS Database study.
    J Neurol. 2026;273:262.
    >> Share

  90. JARIUS S, Ruprecht K, Metz I, Konig FB, et al
    An autoantibody signature predictive for multiple sclerosis: evidence at the protein level and association with histopathological lesion types.
    J Neurol. 2026;273:257.
    >> Share

  91. GLEISNER N, Meda F, Johnsson M, Rosenstein I, et al
    Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain-Barre syndrome: a possible prognostic biomarker for disability at 12 months.
    J Neurol. 2026;273:253.
    >> Share

  92. ZIVADINOV R, Semy M, Bartnik A, Hildesheim FE, et al
    Dura mater enhancement on 3T MRI is associated with cortical lesion burden in multiple sclerosis.
    J Neurol. 2026;273:251.
    >> Share

  93. FILIPPAKOPOULOU E, Gavriilaki M, Arnaoutoglou M, Kimiskidis V, et al
    Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis.
    J Neurol. 2026;273:244.
    >> Share

  94. NERI F, Bianchi A, Luchetti L, Breccia D, et al
    Functional head impulse testing for detection and quantification of vestibular dysfunction in multiple sclerosis.
    J Neurol. 2026;273:245.
    >> Share

  95. HAYES MTG, Beadnall HN, Merlo D, Monif M, et al
    Cross-sectional brain volumetric measures and disability outcomes in relapsing-remitting multiple sclerosis.
    J Neurol. 2026;273:243.
    >> Share

  96. GUO J, Olsson T, Johansson E, Alfredsson L, et al
    Long-term disability after initiation of platform versus high-efficacy disease-modifying therapy in relapsing-onset multiple sclerosis.
    J Neurol. 2026;273:240.
    >> Share

  97. DAMMAN SF, Rai SM, Shrestha R, Shaikh AG, et al
    Alternative diagnoses in patients referred to neuroimmunology for autoimmune encephalitis evaluation.
    J Neurol. 2026;273:239.
    >> Share

    March 2026
  98. MONTALBAN X, Hohlfeld R, Pozzilli C, Freedman MS, et al
    Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.
    J Neurol. 2026;273:234.
    >> Share

  99. ANDERSEN LK, Birnbaum S, Missel M, Petersen KG, et al
    Assessing respiratory status in myasthenia gravis: limited value of the MG-ADL as a standalone tool compared with spirometry in a Danish cohort.
    J Neurol. 2026;273:231.
    >> Share

  100. FALSO S, Spagni G, Monte G, Marini S, et al
    Half a century of change: demographic trends and their clinical impact in acetylcholine receptor antibody-positive myasthenia gravis.
    J Neurol. 2026;273:227.
    >> Share

  101. YEH WZ, Francis A, Butzkueven H, Geraldes R, et al
    Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score.
    J Neurol. 2026;273:224.
    >> Share

  102. CAO Z, Hou H, Liu H, Li B, et al
    Clinical characteristics of autoimmune GFAP astrocytopathy with concomitant Epstein-Barr virus positivity: a case series of 12 patients and literature review.
    J Neurol. 2026;273:221.
    >> Share

  103. MISCIOSCIA A, Silvestri E, Puthenparampil M, Scialpi G, et al
    The cerebellar cognitive affective syndrome scale in early multiple sclerosis.
    J Neurol. 2026;273:219.
    >> Share

  104. WIENDL H, Gold R, Pul R, Ernst M, et al
    Treatment-free remission in MS: long-term disease control with cladribine tablets.
    J Neurol. 2026;273:218.
    >> Share

  105. ZHANG X, Xiong X, Wei J, Yan Y, et al
    Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study.
    J Neurol. 2026;273:212.
    >> Share

  106. FUJII S, Yaguchi H, Kudo A, Eguchi K, et al
    Prevalence and profiles of clinically diagnosed autoimmune cerebellar ataxia in a Japanese nationwide survey.
    J Neurol. 2026;273:215.
    >> Share

  107. GUERRA T, Lucisano G, Rocca MA, Cocco E, et al
    HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS.
    J Neurol. 2026;273:193.
    >> Share

  108. DIMITRIADOU EM, Tzanetakos D, Theodorou A, Akrivaki A, et al
    The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naive patients with multiple sclerosis.
    J Neurol. 2026;273:194.
    >> Share

  109. CANDELORO R, Laudisi M, Ferri C, Baldi E, et al
    Beyond oligoclonal bands: the independent role of kappa free light chains in the diagnostic workup of multiple sclerosis.
    J Neurol. 2026;273:191.
    >> Share

  110. FREEDMAN DE, Benedict RHB, Oh J, Feinstein A, et al
    The non-linear relationship between self-reported cognitive concerns and performance-based cognitive dysfunction in people with multiple sclerosis: a cross-sectional study.
    J Neurol. 2026;273:190.
    >> Share

  111. MOLENAAR PCG, de Jong DJ, Hof SN, van Oirschot P, et al
    Digital monitoring of disease activity in relapsing-remitting multiple sclerosis.
    J Neurol. 2026;273:186.
    >> Share

  112. MIEGEL L, Hickstein J, Reibelt A, Heesen C, et al
    Myasthenia gravis and pregnancy: a systematic review and meta-analysis.
    J Neurol. 2026;273:184.
    >> Share

  113. KLEIN KRANENBARG RAM, Blok KM, van Hasselt Y, Melisse S, et al
    Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS.
    J Neurol. 2026;273:182.
    >> Share

  114. KLOSTERMANN F, Steiner OL
    Non-sensorimotor symptoms in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2026;273:178.
    >> Share

  115. RICE C, Scolding N
    Primary central nervous system vasculitis: an update.
    J Neurol. 2026;273:179.
    >> Share

  116. BERGAMASCHI R, Ferraro OE, Enrico P, Marzia F, et al
    Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.
    J Neurol. 2026;273:172.
    >> Share

    February 2026
  117. OEZTUERK M, Huntemann N, Gerischer L, Herdick M, et al
    Early versus late add-on therapy in generalized myasthenia gravis: a multicenter real-world cohort study.
    J Neurol. 2026;273:168.
    >> Share

  118. PELOUTO F, Papri N, Haagsma JA, Cornblath DR, et al
    Measurement properties of the Inflammatory Rasch-built Overall Disability Scale (I-RODS) in patients with Guillain-Barre syndrome.
    J Neurol. 2026;273:164.
    >> Share

  119. PRESSLER H, Schwarz L, Streit S, Aigner A, et al
    Clinical course and prognosis of chronic autoimmune neuropathies requiring intensive care: a retrospective cohort study.
    J Neurol. 2026;273:165.
    >> Share

  120. SANDROFF BM, Motl RW, Nauman H, Wells GE, et al
    Feasibility of a 12-month, remotely delivered and supported aerobic walking exercise training program for brain and cognition in adults with multiple sclerosis.
    J Neurol. 2026;273:162.
    >> Share

  121. GUO J, Olsson T, Alfredsson L, Hedstrom AK, et al
    Disability progression in multiple sclerosis: a latent class analysis of predictors.
    J Neurol. 2026;273:157.
    >> Share

  122. LIN J, Chang T, Xiao L, Hu J, et al
    Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study.
    J Neurol. 2026;273:146.
    >> Share

  123. QU B, Li S, Chen H, Zhang Y, et al
    Disrupted and reorganized connectivity of brain networks in multiple sclerosis: a systematic review and meta-analysis of resting-state functional MRI.
    J Neurol. 2026;273:139.
    >> Share

  124. VAN DEN BOOGAARD LJM, Bochman A, Drenthen GS, Knippenberg SAM, et al
    Longitudinal myelin MR imaging in patients with multiple sclerosis: a narrative review.
    J Neurol. 2026;273:136.
    >> Share

  125. LIN PH, Zhang SF, Yao HY, Lai WD, et al
    Neuronal antibody targeting metabotropic glutamate receptor 8 in five cases and its pathogenicity.
    J Neurol. 2026;273:134.
    >> Share

  126. CORSTEN CEA, Geraedts VSA, Marques AM, Melief MJ, et al
    Serum neurofilament light chain and glial fibrillary acidic protein predicting multiple sclerosis after clinically isolated syndrome.
    J Neurol. 2026;273:128.
    >> Share

  127. FREEDMAN DE, Oh J, Feinstein A
    Relationship status and the neurobehavioral symptoms of multiple sclerosis: a cross-sectional analysis.
    J Neurol. 2026;273:126.
    >> Share

  128. LIN L, Fang L, Huang Y, Luo Q, et al
    Brain imaging reveals hierarchical topology changes and stage-dependent impairments in autoimmune encephalitis.
    J Neurol. 2026;273:125.
    >> Share

  129. GERNERT JA, Zausinger H, Diedrich L, Wicklein R, et al
    The potential of optical coherence tomography angiography in progressive multiple sclerosis.
    J Neurol. 2026;273:118.
    >> Share

  130. GUO J, Olsson T, Alfredsson L, Hedstrom AK, et al
    Patient-reported gradual worsening reveals progression beyond MS subtypes.
    J Neurol. 2026;273:117.
    >> Share

  131. SAJIN V, Bohringer MP, Ebert J, Wandinger KP, et al
    A patient with anti-IgLON5 disease associated with cerebral hemorrhage, multiple ischemic strokes, and kidney failure: case report.
    J Neurol. 2026;273:116.
    >> Share

  132. SOUISSI A, Patti F, Spelman T, Chisari C, et al
    Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.
    J Neurol. 2026;273:114.
    >> Share

  133. MARGONI M, Gueye M, Meani A, Pagani E, et al
    Substrates of 8.5-year clinical outcomes in aquaporin-4 IgG-positive neuromyelitis optica spectrum disorders.
    J Neurol. 2026;273:112.
    >> Share

    January 2026
  134. ZANETTA C, Giordano A, Laserra F, Giliberti A, et al
    Environmental risk factors and conversion to multiple sclerosis in subjects with radiologically isolated syndrome: a case-control study.
    J Neurol. 2026;273:106.
    >> Share

  135. ALADRO Y, Alvarez-Saenz de Tejada C, Diaz-Diaz J, Pilo de la Fuente B, et al
    Prevalence of restless legs syndrome in patients with multiple sclerosis, as confirmed by sleep disorders specialists.
    J Neurol. 2026;273:96.
    >> Share

  136. BAIAMONTE L, Sera F, Bellante G, Ragonese P, et al
    Accuracy of the central vein sign in diagnosis of multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2026;273:95.
    >> Share

  137. GYGER N, Monschein T, Filser M, Batge S, et al
    Cognitive training, exercise training or combined training? A comparative effectiveness research study on subjective and objective cognitive outcomes in multiple sclerosis.
    J Neurol. 2026;273:82.
    >> Share

  138. GRECO G, Della Porta G, Masi F, Redemagni C, et al
    Two-year OCT follow-up in multiple sclerosis patients on Ofatumumab shows retinal preservation over non-antiCD20 treatments.
    J Neurol. 2026;273:77.
    >> Share

  139. ZENG K, Chen W, Lin A
    Eculizumab as a rescue therapy in acute-phase aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder.
    J Neurol. 2026;273:73.
    >> Share

  140. KOC ER, Yetkin MF, Saridas F, Turan OF, et al
    Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    J Neurol. 2026;273:67.
    >> Share

  141. RUST R, Asseyer S, Schindler P, Chien C, et al
    Cognitive function in patients with myelin oligodendrocyte glycoprotein antibody-associated disease.
    J Neurol. 2026;273:61.
    >> Share

  142. SICONOLFI G, Primiano G, Vitali F, Sciarrone MA, et al
    Serum Galectin-3 as a biomarker in acute inflammatory polyradiculoneuropathies: a cohort study.
    J Neurol. 2026;273:56.
    >> Share

    December 2025
  143. YANG J, Li H, Zhang Y, Hu S, et al
    Correction: Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
    J Neurol. 2025;273:51.
    >> Share

  144. CHISARI CG, Lo Fermo S, Di Sapio A, Amato MP, et al
    Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study).
    J Neurol. 2025;273:47.
    >> Share

  145. RESTUCCIA G, Susinna C, Marafioti G, Rifici C, et al
    Serum and cerebrospinal fluid biomarkers as predictors of cognitive impairment in multiple sclerosis: a systematic review of longitudinal studies.
    J Neurol. 2025;273:36.
    >> Share

  146. SURCINELLI A, Massa I, Gentili N, Panzera I, et al
    Harmonized magnetic resonance imaging protocols for multiple sclerosis: HARMONY-MS, a pilot project.
    J Neurol. 2025;273:39.
    >> Share

  147. KONITSIOTI AM, Schweitzer F, Johannis W, Steffen F, et al
    Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens.
    J Neurol. 2025;273:34.
    >> Share

  148. LU C, Lin Y, Wu M, Chen J, et al
    Brain atrophy in autoimmune encephalitis: epidemiology, pathophysiology, clinical manifestations, treatment, and prognosis-an update.
    J Neurol. 2025;273:32.
    >> Share

  149. CABON J, Ducloie M, Chretien B, Arnaud C, et al
    Guillain-Barre syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study.
    J Neurol. 2025;273:27.
    >> Share

  150. TAN H, Yin Z, Zhangbao J, Li X, et al
    Retinal nerve fiber layer thinning in multiple sclerosis: clinical implications, cognitive associations, and effects of disease-modifying therapies.
    J Neurol. 2025;273:25.
    >> Share

  151. BSTEH G, Velez Escola L, Hegen H, Lindner E, et al
    Application of optical coherence tomography in multiple sclerosis: consensus recommendations of the Austrian network (AN-OCT-MS).
    J Neurol. 2025;273:24.
    >> Share

  152. TEDONE N, Preziosa P, Meani A, Mistri D, et al
    Clinical, functional and cognitive features of late-onset multiple sclerosis.
    J Neurol. 2025;273:14.
    >> Share

  153. ELLINGHAUS CA, Rohling HM, Dorsch EM, Sperber PS, et al
    Anchor-based evaluation of digital motor biomarkers from a 2-year observation in 100 patients with multiple sclerosis.
    J Neurol. 2025;273:4.
    >> Share

  154. HEDSTROM AK, Olsson T, Alfredsson L
    Determinants and prognostic value of onset symptoms in multiple sclerosis.
    J Neurol. 2025;273:2.
    >> Share

    November 2025
  155. WANG Z, Li S, Liu J, Li Y, et al
    Nomograms integrating cortical morphometric metrics with 3D multi-parametric MRI radiomics for predicting disability progression and cognitive worsening in relapsing-remitting multiple sclerosis: a multi-center validation study.
    J Neurol. 2025;272:792.
    >> Share

  156. KLEINSCHNITZ C, Skripuletz T, Pfeuffer S, Pawlitzki M, et al
    Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy.
    J Neurol. 2025;272:788.
    >> Share

  157. PIERVINCENZI C, Ojha A, Tommasin S, Satriano F, et al
    Functional connectivity changes are associated with disability progression in multiple sclerosis: a longitudinal fMRI study.
    J Neurol. 2025;272:787.
    >> Share

  158. ARSLAN D, Colpak AI, Yardimci GK, Bulut EG, et al
    Neurological involvement in IgG4-related disease: focus on neuro-ophthalmologic features.
    J Neurol. 2025;272:785.
    >> Share

  159. BALSHI A, Dempsey JP, Kumbar S, Manning N, et al
    Motherhood and diagnostic delay among women with multiple sclerosis.
    J Neurol. 2025;272:784.
    >> Share

  160. YANG X, Li F, Zhe J, Zhang Z, et al
    Single-cell RNA sequencing of cerebrospinal fluid immune cells in relapsing-remitting multiple sclerosis: insights into cellular composition and immune dynamics.
    J Neurol. 2025;272:778.
    >> Share

  161. TEDONE N, Grosselle M, Portaccio E, Amato MP, et al
    The brief repeatable battery of neuropsychological test (BRB-N) version B: update of Italian normative data.
    J Neurol. 2025;272:776.
    >> Share

  162. MONSCHEIN T, Untersteiner H, Ponleitner M, Krajnc N, et al
    Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR).
    J Neurol. 2025;272:774.
    >> Share

  163. WANG R, Wang X, Shi Z, Kong L, et al
    Severe attacks and worse prognosis in patients with late-onset neuromyelitis optica spectrum disorder highlight the need for early highly effective treatment.
    J Neurol. 2025;272:771.
    >> Share

  164. MARTIRE MS, Gattuso I, Vezzulli P, Guerrieri S, et al
    Unveiling a silent threat: slowly expanding spinal cord lesion linked to clinical worsening in multiple sclerosis: a case report.
    J Neurol. 2025;272:773.
    >> Share

  165. STEINER OL, Angela C, Krasivskaya E, Klostermann F, et al
    Cognitive impairment in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2025;272:769.
    >> Share

  166. LADEIRA F, Nobrega C, Cerqueira J
    Correction: Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
    J Neurol. 2025;272:768.
    >> Share

  167. MESSINA C
    The overlooked side of myasthenia gravis: the non-motor manifestations-a comprehensive review.
    J Neurol. 2025;272:764.
    >> Share

  168. LI X, Gupta P, Paramasivan NK, Flanagan EP, et al
    Development of anti-LGI1 autoimmune encephalitis outcome rating score using the Rasch analysis.
    J Neurol. 2025;272:757.
    >> Share

  169. TROJANO M, Iaffaldano P, Copetti M, Drahota J, et al
    Big multiple sclerosis data network: novel modelling approaches for real-world data analysis.
    J Neurol. 2025;272:754.
    >> Share

  170. BARNETT-TAPIA C, Cortes Vicente E, Pascuzzi RM, Utsugisawa K, et al
    Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study.
    J Neurol. 2025;272:752.
    >> Share

  171. OZAKBAS S, Alizada S, Caliskan C, Simsek Y, et al
    Familial multiple sclerosis is associated with accelerated progression to secondary progressive phase: a retrospective single-center cohort study.
    J Neurol. 2025;272:749.
    >> Share

  172. WASKOWIAK PT, de Jong BA, Uitdehaag BMJ, Myronenko A, et al
    Cognitive awareness in people with multiple sclerosis before and after neuropsychological assessment.
    J Neurol. 2025;272:748.
    >> Share

  173. MATAS E, Bau L, Romero-Pinel L, Leon I, et al
    Benign multiple sclerosis and long-term outcomes after 30 years.
    J Neurol. 2025;272:747.
    >> Share

    October 2025
  174. TAN Y, Lu J, Zhang J, Qi X, et al
    Efgartigimod-rituximab sequential therapy in Anti-NMDAR encephalitis: real-world evidence for a novel salvage-maintenance strategy.
    J Neurol. 2025;272:739.
    >> Share

  175. LI Y, Zhou Q, Dong X, Duan W, et al
    Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.
    J Neurol. 2025;272:736.
    >> Share

  176. MONTE G, Tiralongo G, Papetti L, Ferilli MAN, et al
    Complete Epstein-Barr virus seropositivity in a cohort of pediatric onset multiple sclerosis: a comparison to other autoimmune diseases.
    J Neurol. 2025;272:735.
    >> Share

  177. PALAZZO L, Cetta I, Bongiovanni L, Gastaldi M, et al
    Clinical and neuroradiological evolution of thymoma-associated anti-GABAA receptor autoimmune encephalitis: insights from a clinical case report.
    J Neurol. 2025;272:733.
    >> Share

  178. HUA LH, Brown B, Camacho E, Chinea AR, et al
    Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study.
    J Neurol. 2025;272:725.
    >> Share

  179. ABOSEIF A, Jackson-Tarlton CS, Schwarz CG, Decker PA, et al
    Cervical cord atrophy correlates with intracranial lesion burden in tumefactive multiple sclerosis.
    J Neurol. 2025;272:717.
    >> Share

  180. LATINI E, Guida M, Zirafa CC, Rizzo S, et al
    Long-term effectiveness of thymectomy in late-onset myasthenia gravis.
    J Neurol. 2025;272:714.
    >> Share

  181. OPFER R, Spies L, Kruger J, Buddenkotte T, et al
    Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis.
    J Neurol. 2025;272:715.
    >> Share

  182. SU X, Zheng Z, Yu F, Liu C, et al
    The impact of different exercise types on cognitive function in patients with multiple sclerosis: a systematic review and network meta-analysis.
    J Neurol. 2025;272:709.
    >> Share

  183. PREZIOSA P, Brescia Morra V, Capobianco M, Gasperini C, et al
    Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion.
    J Neurol. 2025;272:707.
    >> Share

  184. LIU R, Kong L, Cao L, Wang H, et al
    Retinal microvascular differences between multiple sclerosis and neuromyelitis optica spectrum disorder: a cross-sectional study with diagnostic modeling.
    J Neurol. 2025;272:700.
    >> Share

  185. BRIL V, Antozzi C, Berkowicz T, Druzdz A, et al
    Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study.
    J Neurol. 2025;272:686.
    >> Share

  186. TUNC A, Koc ER, Carnero Contentti E, Gomez Figueroa E, et al
    Predictors of relapse and disability in NMOSD, MOGAD, and double-seronegative demyelinating syndromes: an international multicenter retrospective cohort study.
    J Neurol. 2025;272:680.
    >> Share

  187. AHMAD R, Jackson-Tarlton CS, Flanagan EP, Messina S, et al
    Critical demyelinating lesions in progressive multiple sclerosis: a prospective observational study.
    J Neurol. 2025;272:677.
    >> Share

    September 2025
  188. KO KY, Kazzi C, Seery N, Griffith S, et al
    Subjective psychiatric symptoms in post-acute autoimmune encephalitis: findings from the Australian autoimmune encephalitis consortium.
    J Neurol. 2025;272:665.
    >> Share

  189. WAGSHUL ME, Nayak S, Foley FW, Motl RW, et al
    Grey matter atrophy patterns of mobility shared across older adults with and without multiple sclerosis.
    J Neurol. 2025;272:656.
    >> Share

  190. YANG X, Jia Z, Lian X, Zhang R, et al
    Ofatumumab treatment in patients with neuromyelitis optica spectrum disorder: a retrospective multicenter cohort study.
    J Neurol. 2025;272:655.
    >> Share

  191. ROMANO F, Rocca MA, Pagani E, Amato MP, et al
    Effects of cognitive rehabilitation and exercise on brain structure in progressive multiple sclerosis: results from the CogEx trial.
    J Neurol. 2025;272:645.
    >> Share

  192. MORENO-NAVARRO L, Mora-Diaz S, Ruiz-Escribano-Menchen L, Sempere AP, et al
    Kappa free light chain index as a diagnostic and prognostic biomarker in multiple sclerosis.
    J Neurol. 2025;272:646.
    >> Share

  193. HABEK M, Adamec I, Gabelic T, Barun B, et al
    Diagnostic performance of the 2010, 2017, and 2024 McDonald criteria: clinical implications in multiple sclerosis.
    J Neurol. 2025;272:637.
    >> Share

  194. CHEN Y, Xie L, Cui H, Zhang Y, et al
    Autoimmune encephalitis with Anti-mGluR1 antibodies: a comprehensive review.
    J Neurol. 2025;272:623.
    >> Share

  195. ALONI R, Dror C, Barazani T, Kalron A, et al
    Wartime stress and relapse risk in people with multiple sclerosis: a prospective cohort study.
    J Neurol. 2025;272:619.
    >> Share

  196. ZHU W, Chen Y, Tian C, Wang J, et al
    Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.
    J Neurol. 2025;272:622.
    >> Share

  197. YANG J, Li H, Zhang Y, Hu S, et al
    Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
    J Neurol. 2025;272:621.
    >> Share

  198. JU Y, Geng C, Guan H
    Initiation of tocilizumab within 24 hours in acute necrotizing encephalopathy is related to a good outcome: a systematic review.
    J Neurol. 2025;272:618.
    >> Share

  199. ELLENBERGER D, Frahm N, Stahmann A, Warnke C, et al
    Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.
    J Neurol. 2025;272:609.
    >> Share

  200. ASLAN D, Bourabia S, Kowall B, Straukiene A, et al
    The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study.
    J Neurol. 2025;272:607.
    >> Share

  201. KONG L, Tan X, Wang H, Cao L, et al
    Progressive retinal and microvascular neurodegeneration in neuromyelitis optica spectrum disorders: a longitudinal SS-OCT/OCTA study.
    J Neurol. 2025;272:606.
    >> Share

    August 2025
  202. KEVER A, Kang N, Meza C, Pogacar M, et al
    Not for everyone: examining predictors of cognitive rehabilitation success in multiple sclerosis.
    J Neurol. 2025;272:593.
    >> Share

  203. MATHEY G, Epstein J, Alix T, Julien M, et al
    Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.
    J Neurol. 2025;272:592.
    >> Share

  204. ADAMMEK F, Gralla W, Kupjetz M, Rademacher A, et al
    Functional exercise training in persons with multiple sclerosis: a systematic review.
    J Neurol. 2025;272:590.
    >> Share

  205. REEVES JA, Tranquille A, Bartnik A, Mohebbi M, et al
    Paramagnetic rim lesions are associated with choroid plexus inflammation and expansion over 5 years in people with multiple sclerosis.
    J Neurol. 2025;272:585.
    >> Share

  206. SCANDIFFIO J, Langer LK, Senthilnathan V, Feng G, et al
    Effects of psychological therapies in people with multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials.
    J Neurol. 2025;272:584.
    >> Share

  207. GUERRIERI S, Gattuso I, Genchi A, Nozzolillo A, et al
    Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab use.
    J Neurol. 2025;272:583.
    >> Share

  208. ABBADESSA G, Maida E, Bonavita S, Lavorgna L, et al
    First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis.
    J Neurol. 2025;272:582.
    >> Share

  209. SBAIHAT H, Roenneke K, Muller D, Ladopoulos T, et al
    MRI-based human brain atlases of R1, R2, proton density, and myelin volume fraction using synthetic quantitative imaging at 1.5 T.
    J Neurol. 2025;272:578.
    >> Share

  210. JAWORSKI M 3RD, Balconi J, Santivasci C, Youngs M, et al
    Improving conscientiousness through a smartphone app and telecoaching intervention: insights from multiple sclerosis and healthy aging samples.
    J Neurol. 2025;272:580.
    >> Share

  211. ALAM Z, Maddali A, Patel S, Weber N, et al
    Current imaging applications, radiomics, and machine learning modalities of CNS demyelinating disorders and its mimickers.
    J Neurol. 2025;272:568.
    >> Share

  212. ALFREDSSON L, Guo J, Johansson E, Olsson T, et al
    Early-life and adult body mass index in relation to MS disability progression.
    J Neurol. 2025;272:571.
    >> Share

  213. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus.
    J Neurol. 2025;272:565.
    >> Share

  214. JOHN N, Lim A, Sunthar SR, Zhang L, et al
    Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis.
    J Neurol. 2025;272:563.
    >> Share

  215. PETERSSON M, Wu J, Berggren F, Schager I, et al
    Impact of disease activity on quality of life and EQ-5D-3L score in myasthenia gravis: results from the Swedish MG registry.
    J Neurol. 2025;272:562.
    >> Share

  216. LEITNER U, Chew SH, Blanch J, Viswanathan M, et al
    Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2025;272:560.
    >> Share

  217. MANISCALCO GT, Sparaco M, Di Gregorio M, Cafasso G, et al
    Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study.
    J Neurol. 2025;272:559.
    >> Share

  218. KERITAM O, Ascoli O, Harsanyi A, Cetin H, et al
    Advanced multiple sclerosis: an exploratory study on a neglected patient population.
    J Neurol. 2025;272:553.
    >> Share

  219. CHEN Q, Ma Y, Li Z, Yu C, et al
    Distributions and network changes of brain activity in the acute phase of anti-NMDAR encephalitis: a MEG study.
    J Neurol. 2025;272:551.
    >> Share

  220. MENASCU S, Drori T, Kalron A
    Subcortical brain volume changes linked to concern of falling in multiple sclerosis: a structural MRI study.
    J Neurol. 2025;272:552.
    >> Share

    July 2025
  221. DE SOUZA WAGNER PH, de Paiva FA, Mello JS, Silva ALM, et al
    Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis.
    J Neurol. 2025;272:546.
    >> Share

  222. HOU Y, Zhao B, Zheng J, Dai T, et al
    Clinicopathological profiling and prognosis of idiopathic inflammatory myopathy overlapping with myasthenia gravis: a retrospective cohort study.
    J Neurol. 2025;272:542.
    >> Share

  223. DINI M, Tacchini M, Gamberini G, Boschetti A, et al
    Learning as a digital hallmark of cognition in multiple sclerosis: lessons from a digital symbol digit modalities test.
    J Neurol. 2025;272:536.
    >> Share

  224. FUNG WH, Wessels MHJ, Coerver EME, de Beukelaar J, et al
    Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).
    J Neurol. 2025;272:530.
    >> Share

  225. PAUL F, Zappacosta S, Narduzzi S, Khellaf M, et al
    Management and burden of disease in people with myelin oligodendrocyte glycoprotein antibody-associated disease: data from an international, cross-sectional survey.
    J Neurol. 2025;272:529.
    >> Share

  226. DAI Y, Yin Q, Han B, Yuan T, et al
    MOG-IgG detection in serum and cerebrospinal fluid: diagnostic implications and clinical correlates in adult-onset Chinese MOGAD patients.
    J Neurol. 2025;272:528.
    >> Share

  227. WANG R, Wang X, Sun D, Shi Z, et al
    Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD.
    J Neurol. 2025;272:521.
    >> Share

  228. DONEDDU PE, Moretti G, Di Stefano V, Falzone Y, et al
    Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis.
    J Neurol. 2025;272:515.
    >> Share

  229. VITTURI BK, Cellerino M, Boccia D, Leray E, et al
    Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis.
    J Neurol. 2025;272:513.
    >> Share

  230. RUBIN M, Cutillo G, Viti V, Margoni M, et al
    MOGAD-related epilepsy: a systematic characterization of age-dependent clinical, fluid, imaging and neurophysiological features.
    J Neurol. 2025;272:508.
    >> Share

  231. COLEMAN A, Touze A, Farag M, Pengo M, et al
    Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases.
    J Neurol. 2025;272:501.
    >> Share

  232. HELLMANN MA, Steiner I, Mermelstein M, Friedman I, et al
    Familial myasthenia gravis: characterization of an Israeli cohort and systematic review of the literature.
    J Neurol. 2025;272:498.
    >> Share

  233. NICOLELLA V, Varelli M, Fasano S, Sirica R, et al
    Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis.
    J Neurol. 2025;272:495.
    >> Share

  234. YAGIZ OZOGUL Y, Esatoglu SN, Ozogul M, Kizilkilic O, et al
    Central nervous system involvement and mimickers in ANCA associated vasculitis.
    J Neurol. 2025;272:492.
    >> Share

  235. CAGOL A, Schaedelin S, Ocampo-Pineda M, Benkert P, et al
    Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort.
    J Neurol. 2025;272:491.
    >> Share

  236. WANG Y, Nao J, Duan Y, Li Z, et al
    Therapeutic strategies targeting complement in myasthenia gravis patients.
    J Neurol. 2025;272:489.
    >> Share

  237. VAN TILBURG SJ, Kocer S, Geissler J, van Rijs W, et al
    Genetic variation of low-to-medium-affinity Fc-gamma receptors in Guillain-Barre syndrome.
    J Neurol. 2025;272:487.
    >> Share

  238. LIMA SM, Rini N, Cali A, Brighina F, et al
    Clonidine for the management of crises in stiff-person syndrome.
    J Neurol. 2025;272:485.
    >> Share

    June 2025
  239. ZACCONE T, Moiola L, Guerrieri S, Nozzolillo A, et al
    Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study.
    J Neurol. 2025;272:481.
    >> Share

  240. VERCELLINO M, Marasciulo S, Bosa C, Rolando A, et al
    Added value of spinal cord MRI in detecting active disease in non-relapsing progressive multiple sclerosis patients.
    J Neurol. 2025;272:482.
    >> Share

  241. NAUTA IM, Loughlin KNM, Gravesteijn AS, van Wegen J, et al
    A multi-domain lifestyle intervention in multiple sclerosis: a longitudinal observational study.
    J Neurol. 2025;272:476.
    >> Share

  242. VORASOOT N, Isitan-Alkawadri C, Pillai B, Miske R, et al
    DAGLA autoantibody experience at Mayo Clinic.
    J Neurol. 2025;272:460.
    >> Share

  243. HEWAMADDUMA C, Freimer M, Genge A, Leite MI, et al
    Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.
    J Neurol. 2025;272:457.
    >> Share

  244. BURGUET VILLENA F, Cerda-Fuertes N, Hofer L, Schadelin S, et al
    Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis.
    J Neurol. 2025;272:454.
    >> Share

  245. SAMADZADEH S, Chan F, Francis A, Sani L, et al
    The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD.
    J Neurol. 2025;272:453.
    >> Share

  246. HERAUD C, Bresch S, Bourg V, Landes-Chateau C, et al
    Monitoring anti-Rituximab antibodies in myasthenia gravis affects the time to event during Rituximab treatment.
    J Neurol. 2025;272:451.
    >> Share

  247. ZANETTA C, Gasperini C, Amato MP, Centonze D, et al
    Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective.
    J Neurol. 2025;272:446.
    >> Share

  248. CHEN H
    A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).
    J Neurol. 2025;272:445.
    >> Share

  249. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
    Correction: In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
    J Neurol. 2025;272:444.
    >> Share

  250. GERAN R, Steiner OL, Krasivskaya E, Hannemann U, et al
    Inverse relation between serum neurofilament light chain and cognitive function in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2025;272:439.
    >> Share

    May 2025
  251. MACCORA S, Vinciguerra C, Messina C, Bevilacqua L, et al
    Double seronegative myasthenia gravis and mimics: a retrospective cross-sectional study by two tertiary centers in the Southern Italy.
    J Neurol. 2025;272:433.
    >> Share

  252. NEYAL N, Krey KJ, Morrison HA, Nathoo N, et al
    From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis.
    J Neurol. 2025;272:434.
    >> Share

  253. GASPERINI C, Centonze D, Conte A, Gallo P, et al
    Personalized therapy in multiple sclerosis: an Italian Delphi consensus.
    J Neurol. 2025;272:428.
    >> Share

  254. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
    Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
    J Neurol. 2025;272:423.
    >> Share

  255. ARZALLUZ-LUQUE J, Dumez P, Picard G, Benaiteau M, et al
    Clinical course and long-term outcomes in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy.
    J Neurol. 2025;272:421.
    >> Share

  256. GIOFRE F, Lugaresi A, Baccari F, Lui E, et al
    The topography of infratentorial lesions in depression and anxiety in multiple sclerosis.
    J Neurol. 2025;272:420.
    >> Share

  257. PIGNOLO A, Vinciguerra C, Monastero R, Rini N, et al
    Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review.
    J Neurol. 2025;272:417.
    >> Share

  258. DAVIES L, Shehadeh R, Watkins WJ, Jolles S, et al
    Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis.
    J Neurol. 2025;272:415.
    >> Share

  259. CAO S, Zhou X, Du J, Zhang J, et al
    Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.
    J Neurol. 2025;272:406.
    >> Share

  260. ZHANG Y, Li G, Su H, Liang Y, et al
    Effects of exercise on balance function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2025;272:405.
    >> Share

  261. GERVASONI E, Torchio A, Bertoni R, Chieffo R, et al
    Beyond EDSS: multidomain impairments are detectable and associated with walking disorders in low-disabled people with multiple sclerosis.
    J Neurol. 2025;272:404.
    >> Share

  262. WANG Z, Tan H, Huang W, Fan Y, et al
    Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder.
    J Neurol. 2025;272:403.
    >> Share

  263. FREEDMAN MS, Abdelhak A, Bhutani MK, Freeman J, et al
    The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review.
    J Neurol. 2025;272:400.
    >> Share

  264. KIM YS, Shin IJ, Park DG, Yoon JH, et al
    Hashimoto's encephalopathy with diffuse leukoencephalopathy: serial MRI and gait analysis.
    J Neurol. 2025;272:399.
    >> Share

  265. ROSSINI E, Di Stefano V, Iorio R, Habetswallner F, et al
    Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience.
    J Neurol. 2025;272:396.
    >> Share

  266. TARANU D, Balz LT, Holbrook J, Tumani V, et al
    Cognitive impairment, mood, and fatigue in various multiple sclerosis subtypes: a one-year follow-up study.
    J Neurol. 2025;272:398.
    >> Share

  267. ROCCA MA, Ratzinger S, Preziosa P, Meani A, et al
    Clinical integration of brain and cord MRI features improves differential diagnosis of multiple sclerosis.
    J Neurol. 2025;272:388.
    >> Share

  268. HU S, Liao Z, Wang R, Zhang M, et al
    Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.
    J Neurol. 2025;272:387.
    >> Share

  269. FILIPPI M, Preziosa P, Rocca MA
    Randomized controlled trials for multiple sclerosis: integrating pathology-driven outcomes to capture therapeutic efficacy.
    J Neurol. 2025;272:385.
    >> Share

  270. ROY S, Huang Y, Hu C, Fitzgerald KC, et al
    Core diagnostic features of stiff person syndrome: insights from a case-control study.
    J Neurol. 2025;272:377.
    >> Share

  271. FREEDMAN DE, Oh J, Einstein G, Feinstein A, et al
    Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.
    J Neurol. 2025;272:375.
    >> Share

  272. KOLB H, Shachaf Y, Fainberg K, Golan M, et al
    Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.
    J Neurol. 2025;272:374.
    >> Share

  273. HERMAN D, Tanniou J, Leray E, Pierret C, et al
    Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database.
    J Neurol. 2025;272:371.
    >> Share

  274. KUUTTI K, Laakso SM, Viitala M, Atula S, et al
    Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study.
    J Neurol. 2025;272:370.
    >> Share

    April 2025
  275. CACCIAGUERRA L, Madhavan A, Sechi E, Krecke KN, et al
    Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis.
    J Neurol. 2025;272:367.
    >> Share

  276. PANE C, Di Stefano V, Cuomo N, Sarnataro A, et al
    Correction: A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    J Neurol. 2025;272:366.
    >> Share

  277. SEERY N, Wesselingh R, Beech P, Broadley J, et al
    Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium study.
    J Neurol. 2025;272:361.
    >> Share

  278. MAHMOUDI N, Renne J, Konen FF, Jendretzky KF, et al
    Added value of optic nerve lesions for multiple sclerosis diagnostic criteria.
    J Neurol. 2025;272:358.
    >> Share

  279. CAMPETELLA L, Smolik K, Farina A, Joubert B, et al
    Neurodegeneration and the immune system: lessons from autoimmune encephalitis.
    J Neurol. 2025;272:359.
    >> Share

  280. SIRIRATNAM P, Huda S, Van der Walt A, Sanfilippo P, et al
    Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.
    J Neurol. 2025;272:339.
    >> Share

  281. LEAVITT V, Mostert J, Comtois J, Moral E, et al
    Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.
    J Neurol. 2025;272:338.
    >> Share

  282. BALSHI A, Dempsey J, Kumbar S, Leuenberger G, et al
    Correction: Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
    J Neurol. 2025;272:337.
    >> Share

  283. OJHA A, Tommasin S, Piervincenzi C, Baione V, et al
    Clinical and MRI features contributing to the clinico-radiological dissociation in a large cohort of people with multiple sclerosis.
    J Neurol. 2025;272:327.
    >> Share

  284. HONG J, Gaubert M, Lefort M, Ferre JC, et al
    Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up.
    J Neurol. 2025;272:316.
    >> Share

  285. MOIOLA L, Mandelli A, Tarkowski M, Finardi A, et al
    Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab.
    J Neurol. 2025;272:314.
    >> Share

  286. LADOPOULOS T, Abbas Z, Krieger B, Bellenberg B, et al
    Neurological disability and brain grey matter atrophy in primary progressive multiple sclerosis are determined by microstructural lesional changes, but not by lesion load.
    J Neurol. 2025;272:302.
    >> Share

    March 2025
  287. KONITSIOTI AM, Laurent S, Ellenberger D, Stahmann A, et al
    MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.
    J Neurol. 2025;272:294.
    >> Share

  288. KHERBEK H, Paramasivan NK, Dasari S, Karsten C, et al
    Exploring autoantigens in autoimmune limbic encephalitis using phage immunoprecipitation sequencing.
    J Neurol. 2025;272:292.
    >> Share

  289. RITTEL JC, Hudasch D, Doppler K, Bergh FT, et al
    Intravenous immunoglobulin as first-line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2.
    J Neurol. 2025;272:287.
    >> Share

  290. LADEIRA F, Nobrega C, Cerqueira J
    Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
    J Neurol. 2025;272:288.
    >> Share

  291. FUJII S, Yaguchi H, Kudo A, Eguchi K, et al
    Autoimmune cerebellar ataxia with Kelch-like protein 11 antibodies in a large cohort study.
    J Neurol. 2025;272:282.
    >> Share

  292. FARINA A, Villagran-Garcia M, Abichou-Klich A, Benaiteau M, et al
    Application of the anti-IgLON5 disease composite score to assess severity, clinical course, and mortality in a French cohort.
    J Neurol. 2025;272:273.
    >> Share

  293. BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
    Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study.
    J Neurol. 2025;272:275.
    >> Share

  294. DING Y, Wu D, Chu H, Tang Y, et al
    Clinical characterization of diseases associated with anti-N-methyl-D-aspartate receptor encephalitis combined with anti-myelin oligodendrocyte glycoprotein antibodies in adults.
    J Neurol. 2025;272:262.
    >> Share

  295. SORENSEN NV, Nilsson AC, Dos AH, Stenor CM, et al
    Anti-GFAP associated opsoclonus-myoclonus-ataxia syndrome in a patient with multiple autoimmune comorbidities-a case report.
    J Neurol. 2025;272:263.
    >> Share

  296. KOMATSU T, Motegi H, Mimori M, Okumura M, et al
    Predictors of achieving minimal manifestations or better status in ocular myasthenia gravis with immunotherapy.
    J Neurol. 2025;272:243.
    >> Share

  297. BOSTAN M, Li C, Cheong JW, Wong DWK, et al
    Longitudinal analysis of retinal and choriocapillaris in patients with multiple sclerosis: a 3-year study.
    J Neurol. 2025;272:237.
    >> Share

    February 2025
  298. AZZIMONTI M, Preziosa P, Pagani E, Meani A, et al
    Cervical spinal cord gray matter damage predicts disability worsening in multiple sclerosis: a longitudinal study.
    J Neurol. 2025;272:228.
    >> Share

  299. PARAMASIVAN NK, Sarker P, Zekeridou A, Staff NP, et al
    Upper motor neuron-predominant motor neuron disease: a novel immunotherapy-responsive association of GAD65 autoimmunity.
    J Neurol. 2025;272:230.
    >> Share

  300. BINKS SNM, Morse IM, Ashraghi M, Vincent A, et al
    Myasthenia gravis in 2025: five new things and four hopes for the future.
    J Neurol. 2025;272:226.
    >> Share

  301. SCHONHERR C, Ziegler J, Zentek T, Rashid A, et al
    Smartphone-based gait analysis in the assessment of fatigue and fatigability in people with multiple sclerosis: a supervised cohort study.
    J Neurol. 2025;272:217.
    >> Share

  302. BALSHI A, Dempsey J, Manning N, Leuenberger G, et al
    A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies.
    J Neurol. 2025;272:223.
    >> Share

  303. NAYAK S, Wagshul ME, Foley FW, Motl RW, et al
    Associations between connectivity in functional brain networks and gait speed in older adults with and without multiple sclerosis.
    J Neurol. 2025;272:216.
    >> Share

  304. DI SABATINO E, Ferraro D, Gaetani L, Emiliano E, et al
    CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.
    J Neurol. 2025;272:211.
    >> Share

  305. MARASTONI D, Sicchieri M, Pizzini FB, Scartezzini A, et al
    Multiple sclerosis diagnosis and its differential diagnosis in patients presenting with type four 'mirror pattern' CSF oligoclonal bands.
    J Neurol. 2025;272:207.
    >> Share

  306. NISHIMORI Y, Tanboon J, Oyama M, Motegi H, et al
    Anti-mitochondrial M2 antibody-positive myositis may be an independent subtype of autoimmune myositis.
    J Neurol. 2025;272:206.
    >> Share

  307. CHEN X, Wang R, Li R, Hu S, et al
    A real-world study on the utility of regular rituximab treatment for neuromyelitis optica spectrum disorder.
    J Neurol. 2025;272:194.
    >> Share

  308. FILIPPI M, Amato MP, Avolio C, Gallo P, et al
    Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.
    J Neurol. 2025;272:179.
    >> Share

  309. HANSEL M, Reichmann H, Haehner A, Schmitz-Peiffer H, et al
    Hippocampal dysfunction after autoimmune encephalitis depending on the antibody type.
    J Neurol. 2025;272:175.
    >> Share

    January 2025
  310. GIANNOPAPAS V, Smyrni V, Kitsos DK, Stefanou MI, et al
    Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.
    J Neurol. 2025;272:162.
    >> Share

  311. DE ARMAS FERNANDEZ JR, Garcia CEP, Herrera BA, Garcia FD, et al
    Incidence of Guillain-Barre syndrome in Cuba before and during the Oropouche virus emergency, 2018-2024.
    J Neurol. 2025;272:164.
    >> Share

  312. BOAVENTURA M, Fragoso DC, Avolio I, Pereira SA, et al
    Brain tissue integrity in neuromyelitis optica spectrum disorder through T1-w/T2-w ratio, MTR and DTI.
    J Neurol. 2025;272:157.
    >> Share

  313. INOJOSA H, Schriefer D, Ness NH, Dillenseger A, et al
    Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
    J Neurol. 2025;272:153.
    >> Share

  314. PIHL-JENSEN G, Frederiksen JL
    The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with optic neuritis.
    J Neurol. 2025;272:131.
    >> Share

  315. LAGEMAN SB, Jolly A, Sahi N, Prados F, et al
    Explaining cognitive function in multiple sclerosis through networks of grey and white matter features: a joint independent component analysis.
    J Neurol. 2025;272:142.
    >> Share

  316. MIRMOSAYYEB O, Weinstock-Guttman B, Zivadinov R, Jakimovski D, et al
    Anatomy-driven segmentation of parafoveal optical coherence tomography (OCT) measures may improve associations with clinical outcomes in multiple sclerosis.
    J Neurol. 2025;272:141.
    >> Share

  317. BALSHI A, Dempsey J, Kumbar S, Leunberger G, et al
    Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
    J Neurol. 2025;272:151.
    >> Share

  318. MAR S, Valeriani M, Steinborn B, Schreiner T, et al
    Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
    J Neurol. 2025;272:137.
    >> Share

  319. MAIWORM M, Koerbel K, Anschutz V, Jakob J, et al
    BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients.
    J Neurol. 2025;272:147.
    >> Share

  320. PREZIOSA P, Pagani E, Meani A, Margoni M, et al
    Soma and neurite density abnormalities of paramagnetic rim lesions and core-sign lesions in multiple sclerosis.
    J Neurol. 2025;272:145.
    >> Share

  321. PLESS S, Woelfle T, Lorscheider J, Wiencierz A, et al
    CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis.
    J Neurol. 2025;272:119.
    >> Share

  322. ZANGHI A, Greco A, Giancipoli E, Tumani H, et al
    Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.
    J Neurol. 2025;272:109.
    >> Share

  323. FOCKE JK, Brokbals M, Becker J, Veltkamp R, et al
    Cerebral vasculitis related to neurosarcoidosis: a case series and systematic literature review.
    J Neurol. 2025;272:135.
    >> Share

  324. LIU M, Ren H, Yao D, Yao M, et al
    Autoimmune cerebellar ataxia associated with anti-SEZ6L2 antibody: report of three cases.
    J Neurol. 2025;272:127.
    >> Share

  325. ROBERTSON NP
    Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn.
    J Neurol. 2025;272:106.
    >> Share

  326. FAROOQI AM, Sawalha A, Omidi SJ, Dubey D, et al
    Seizures and status epilepticus in anti-NMDA receptor encephalitis.
    J Neurol. 2025;272:95.
    >> Share

  327. WALBAUM M, Madhukar A, Dobson R, Cyhlarova E, et al
    Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis.
    J Neurol. 2025;272:93.
    >> Share

  328. FILIPPI M, Gallo P, Gasperini C, Marfia GA, et al
    Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.
    J Neurol. 2025;272:96.
    >> Share

  329. SCHUMACHER A, Hieke A, Spenner M, Schmitz F, et al
    Early therapy initiation is crucial in chronic inflammatory demyelinating polyneuropathy: prospective multimodal data from the German INHIBIT registry.
    J Neurol. 2025;272:100.
    >> Share

    December 2024
  330. NICOLESCU M, Haussler V, Paul F, Oertel FC, et al
    Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.
    J Neurol. 2024;272:86.
    >> Share

  331. BARBA L, Gaetani L, Sperandei S, Di Sabatino E, et al
    CSF synaptic biomarkers and cognitive impairment in multiple sclerosis.
    J Neurol. 2024;272:85.
    >> Share

  332. MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al
    Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    J Neurol. 2024;272:77.
    >> Share

  333. INAN B, Ozturk B, Ata N, Ulgu MM, et al
    A nationwide epidemiological study of myasthenia gravis in Turkey.
    J Neurol. 2024;272:5.
    >> Share

  334. VECCHIO D, Puricelli C, Virgilio E, Passarelli F, et al
    Kappa index for multiple sclerosis diagnosis: an accurate biomarker of intrathecal synthesis.
    J Neurol. 2024;272:30.
    >> Share

  335. PONZIO M, Santoni L, Molina M, Tavazzi E, et al
    Economic burden of multiple sclerosis in an Italian cohort of patients on disease-modifying therapy: analysis of disease cost and its components.
    J Neurol. 2024;272:50.
    >> Share

  336. DE BLASIIS P, Massimiani A, Inglese C, Bianchini E, et al
    Spasticity patterns assessment and recognition for therapeutic approaches (SPARTA) in multiple sclerosis: a multicenter epidemiological study.
    J Neurol. 2024;272:34.
    >> Share

  337. KLIMAS R, Sturm D, Altenborg A, Stylianou N, et al
    Assessing axonal pathology and disease progression in chronic inflammatory demyelinating polyneuropathy using corneal confocal microscopy.
    J Neurol. 2024;272:51.
    >> Share

  338. BUGGE C, Engebretsen I, Kristiansen IS, Saether EM, et al
    Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) - a register-based study.
    J Neurol. 2024;272:15.
    >> Share

  339. FASANO C, Bettiol A, Vastola M, Lotti A, et al
    Effectiveness and safety of intravenous immunoglobulin for peripheral neuropathy in EGPA patients: a retrospective study.
    J Neurol. 2024;272:13.
    >> Share

  340. GASPERINI C, Battaglia MA, Balzani F, Chiarini E, et al
    Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals.
    J Neurol. 2024;272:27.
    >> Share

  341. COMABELLA M, Hegen H, Villar LM, Rejdak K, et al
    Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
    J Neurol. 2024;272:26.
    >> Share

  342. MARLET IR, Andersen RK, Axelsen KH, Andersen LK, et al
    Factors affecting the diagnostic delay of myasthenia gravis.
    J Neurol. 2024;272:29.
    >> Share

  343. FILIPPI M, Margoni M, Zaccone T, Guerrieri S, et al
    Disability worsening outcome in multiple sclerosis based on EDSS: does half a point matter?
    J Neurol. 2024;272:9.
    >> Share

    November 2024
  344. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
    Rapid differentiation of MOGAD and MS after a single optic neuritis.
    J Neurol. 2024;271:7222-7231.
    >> Share

    October 2024
  345. FACCIORUSSO S, Malfitano C, Giordano M, Del Furia MJ, et al
    Effectiveness of robotic rehabilitation for gait and balance in people with multiple sclerosis: a systematic review.
    J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12715.
    >> Share

  346. TARD C, Laforet P, de Pouvourville G, Crochard A, et al
    Treatment of myasthenia gravis in france: A retrospective claims database study (STAMINA).
    J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12714.
    >> Share

  347. MOSER T, Gruber J, Mylonaki E, Bohm V, et al
    Autoimmune and infectious encephalitis: development of a discriminative tool for early diagnosis and initiation of therapy.
    J Neurol. 2024 Oct 5. doi: 10.1007/s00415-024-12712.
    >> Share

  348. BALCK A, Lange LM, Neumann A, Royl G, et al
    Highly beneficial outcome in severe acute necrotizing encephalopathy with tocilizumab treatment.
    J Neurol. 2024;271:7042-7045.
    >> Share

  349. SELMAJ K, Hartung HP, Mycko MP, Selmaj I, et al
    MS treatment de-escalation: review and commentary.
    J Neurol. 2024;271:6426-6438.
    >> Share

    September 2024
  350. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
    In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
    J Neurol. 2024 Sep 23. doi: 10.1007/s00415-024-12701.
    >> Share

  351. PEKMEZOVIC T, Jovicevic V, Andabaka M, Momcilovic N, et al
    Aquaporin4-IgG seropositivity significantly increases the risk of comorbid autoimmune diseases in NMOSD patients: population-based registry data.
    J Neurol. 2024 Sep 22. doi: 10.1007/s00415-024-12698.
    >> Share

  352. MARGONI M, Valsasina P, Moiola L, Mistri D, et al
    Monoaminergic network abnormalities are associated with fatigue in pediatric multiple sclerosis.
    J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12689.
    >> Share

  353. MENG H, He L, Chunyu H, Zhou Q, et al
    (18)F-DPA714 PET/MRI as a potential imaging tool for detecting possible antibody-negative autoimmune encephalitis: a prospective study.
    J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12690.
    >> Share

  354. MANGIORIS G, Orozco E, Dubey D, Flanagan EP, et al
    Long-term outcomes in antibody-negative autoimmune encephalitis: a retrospective study.
    J Neurol. 2024 Sep 15. doi: 10.1007/s00415-024-12680.
    >> Share

  355. KONITSIOTI AM, Pruss H, Laurent S, Fink GR, et al
    Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.
    J Neurol. 2024 Sep 14. doi: 10.1007/s00415-024-12642.
    >> Share

  356. YOUSEF H, Malagurski Tortei B, Castiglione F
    Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.
    J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12651.
    >> Share

  357. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
    Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
    J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12608.
    >> Share

  358. HAFSTEINSDOTTIR B, Farman H, Lagerstrom N, Zetterberg H, et al
    Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barre syndrome.
    J Neurol. 2024 Sep 9. doi: 10.1007/s00415-024-12679.
    >> Share

  359. CALLEN AM, Zurawski J, Chu R, Tie Y, et al
    The role of 7 T MRI to assess atrophy of the subcortical deep gray matter in relapsing-remitting multiple sclerosis.
    J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12656.
    >> Share

  360. DELUCA J
    Correction to: Fatigue in multiple sclerosis: can we measure it and can we treat it?
    J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12630.
    >> Share

  361. PORTACCIO E, Betti M, De Meo E, Addazio I, et al
    Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
    J Neurol. 2024 Sep 4. doi: 10.1007/s00415-024-12627.
    >> Share

  362. GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
    Correction to: Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
    J Neurol. 2024 Sep 3. doi: 10.1007/s00415-024-12560.
    >> Share

  363. SHI Z, Kong L, Wang R, Wang X, et al
    Cytomegalovirus and Epstein-Barr virus infections in patients with neuromyelitis optica spectrum disorder.
    J Neurol. 2024;271:6089-6095.
    >> Share

  364. QUINT P, Schroeter CB, Kohle F, Ozturk M, et al
    Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort.
    J Neurol. 2024;271:5930-5943.
    >> Share

  365. HECHLER A, Kuchling J, Muller-Jensen L, Klag J, et al
    Hippocampal hub failure is linked to long-term memory impairment in anti-NMDA-receptor encephalitis: insights from structural connectome graph theoretical network analysis.
    J Neurol. 2024;271:5886-5898.
    >> Share

  366. ABBOUD H, Sun R, Modak N, Elkasaby M, et al
    Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a prospective observational study.
    J Neurol. 2024;271:5875-5885.
    >> Share

    August 2024
  367. WURDACK K, Pruss H, Finke C
    Evolution from viral encephalitis to autoimmune encephalitis to multiple sclerosis: a case report.
    J Neurol. 2024 Aug 31. doi: 10.1007/s00415-024-12659.
    >> Share

  368. CHISARI CG, Amato MP, Di Sapio A, Foschi M, et al
    Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA).
    J Neurol. 2024 Aug 27. doi: 10.1007/s00415-024-12621.
    >> Share

  369. BAYAT M, Harbo T, Anzabi M, Bayat A, et al
    POLG-related mitochondrial disease mimicking autoimmune encephalitis.
    J Neurol. 2024 Aug 24. doi: 10.1007/s00415-024-12641.
    >> Share

  370. CAROTENUTO A, Di Monaco C, Papetti L, Borriello G, et al
    Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.
    J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12610.
    >> Share

  371. SIMONE M, Lucisano G, Guerra T, Paolicelli D, et al
    Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
    J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12638.
    >> Share

  372. MISCIOSCIA A, Mainero C, Treaba CA, Silvestri E, et al
    The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers.
    J Neurol. 2024 Aug 19. doi: 10.1007/s00415-024-12622.
    >> Share

  373. DUMEZ P, Villagran-Garcia M, Bani-Sadr A, Benaiteau M, et al
    Specific clinical and radiological characteristics of anti-NMDA receptor autoimmune encephalitis following herpes encephalitis.
    J Neurol. 2024 Aug 16. doi: 10.1007/s00415-024-12615.
    >> Share

  374. KOKUBUN N, Tsuchiya T, Hamaguchi M, Ueda Y, et al
    IgG subclass shifts occurring at acute exacerbations in autoimmune nodopathies.
    J Neurol. 2024 Aug 2. doi: 10.1007/s00415-024-12597.
    >> Share

  375. ARNETT S, Chew SH, Leitner U, Hor JY, et al
    Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
    J Neurol. 2024;271:4794-4812.
    >> Share

  376. ARNETT SV, Prain K, Ramanathan S, Bhuta S, et al
    Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis.
    J Neurol. 2024;271:5275-5289.
    >> Share

  377. KLIMAS R, Kordes A, Huckemann S, Gasz Z, et al
    The multiple roles of nerve biopsy in the diagnosis and prognosis of suspected immune neuropathies.
    J Neurol. 2024;271:5109-5121.
    >> Share

  378. RECHTMAN A, Freidman-Korn T, Zveik O, Shweiki L, et al
    Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings.
    J Neurol. 2024;271:5102-5108.
    >> Share

  379. ZHANG L, Zhang Y, Li R, Zhu J, et al
    Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic inflammatory demyelinating polyradiculoneuropathy.
    J Neurol. 2024;271:4991-5002.
    >> Share

  380. COLY M, Adams D, Attarian S, Bouhour F, et al
    Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome.
    J Neurol. 2024;271:4982-4990.
    >> Share

  381. ZIVADINOV R, Jakimovski D, Burnham A, Kuhle J, et al
    Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA-MS case-controlled study.
    J Neurol. 2024;271:4949-4962.
    >> Share

    July 2024
  382. PANE C, Di Stefano V, Cuomo N, Sarnataro A, et al
    A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    J Neurol. 2024 Jul 30. doi: 10.1007/s00415-024-12588.
    >> Share

  383. PAPATHANASIOU A, Tench CR, Ambrose PA, Sedehizadeh S, et al
    Pre-thymectomy disease severity predicts outcome in acetylcholine receptor antibody-positive generalised myasthenia gravis.
    J Neurol. 2024 Jul 30. doi: 10.1007/s00415-024-12592.
    >> Share

  384. FILIPPI M, Pagani E, Turrini R, Bartezaghi M, et al
    Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
    J Neurol. 2024 Jul 29. doi: 10.1007/s00415-024-12590.
    >> Share

  385. MANZANO GS, Levy M, Salky R, Mateen FJ, et al
    Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.
    J Neurol. 2024 Jul 27. doi: 10.1007/s00415-024-12585.
    >> Share

  386. MITOMA H, Manto M
    Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel concepts and fundamental questions on autoimmune mechanisms.
    J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12596.
    >> Share

  387. PASSALI M, Galea I, Knudsen MH, Lau LC, et al
    Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis.
    J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12587.
    >> Share

  388. HABIB AA, Klink AJ, Muppidi S, Parthan A, et al
    United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.
    J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12569.
    >> Share

  389. KARL AS, Klimas R, Katsimpoura M, Sgodzai M, et al
    Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study.
    J Neurol. 2024 Jul 22. doi: 10.1007/s00415-024-12581.
    >> Share

  390. MOLENAAR PCG, Noteboom S, van Nederpelt DR, Krijnen EA, et al
    Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
    J Neurol. 2024 Jul 15. doi: 10.1007/s00415-024-12516.
    >> Share

  391. RAVANO V, Andelova M, Piredda GF, Sommer S, et al
    Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis.
    J Neurol. 2024 Jul 13. doi: 10.1007/s00415-024-12568.
    >> Share

  392. VITI V, Zanetta C, Capra R, Municchi A, et al
    Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
    J Neurol. 2024 Jul 11. doi: 10.1007/s00415-024-12553.
    >> Share

  393. ZHU F, Wang WF, Ma CH, Liang H, et al
    Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod.
    J Neurol. 2024 Jul 9. doi: 10.1007/s00415-024-12556.
    >> Share

  394. DELUCA J
    Fatigue in multiple sclerosis: can we measure it and can we treat it?
    J Neurol. 2024 Jul 5. doi: 10.1007/s00415-024-12524.
    >> Share

  395. ROT U, Jerala M, Horvat Ledinek A, Brecl Jakob G, et al
    Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report.
    J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12542.
    >> Share

  396. PREZIOSA P, Amato MP, Battistini L, Capobianco M, et al
    Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.
    J Neurol. 2024;271:3879-3896.
    >> Share

  397. KAPPOS L, Edan G, Freedman MS, Hartung HP, et al
    Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
    J Neurol. 2024;271:4599-4609.
    >> Share

  398. ZANGHI A, Borriello G, Bonavita S, Fantozzi R, et al
    Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
    J Neurol. 2024;271:4495-4502.
    >> Share

  399. WANG R, Sun D, Wang X, Shi Z, et al
    Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
    J Neurol. 2024;271:4503-4512.
    >> Share

  400. HARTUNG HP, Berger T, Bermel RA, Brochet B, et al
    ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
    J Neurol. 2024;271:4348-4360.
    >> Share

  401. PESTCHANKER C, Bertado Cortez B, Lana Peixoto MA, Gortari JI, et al
    Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings.
    J Neurol. 2024;271:4292-4299.
    >> Share

  402. MAKHANI N, Lebrun-Frenay C, Siva A, Shabanova V, et al
    The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.
    J Neurol. 2024;271:4019-4027.
    >> Share

    June 2024
  403. LAL AP, Foong YC, Sanfilippo PG, Spelman T, et al
    A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
    J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518.
    >> Share

  404. GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
    Memory function in autoimmune encephalitis: a cross-sectional prospective study utilising multiple memory paradigms.
    J Neurol. 2024 Jun 25. doi: 10.1007/s00415-024-12520.
    >> Share

  405. NOTEBOOM S, Seiler M, Chien C, Rane RP, et al
    Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
    J Neurol. 2024 Jun 23. doi: 10.1007/s00415-024-12507.
    >> Share

  406. SIMANI L, Molaeipour L, Kian S, Leavitt VM, et al
    Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2024 Jun 18. doi: 10.1007/s00415-024-12517.
    >> Share

  407. FUNKE M, Eveslage M, Zschuntzsch J, Hagenacker T, et al
    Fatigue and associated factors in myasthenia gravis: a nationwide registry study.
    J Neurol. 2024 Jun 13. doi: 10.1007/s00415-024-12490.
    >> Share

  408. YU H, Wang X, Pan Y, Li H, et al
    Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.
    J Neurol. 2024 Jun 12. doi: 10.1007/s00415-024-12494.
    >> Share

  409. KONG X, Guo K, Liu X, Gong X, et al
    Differentiation between viral and autoimmune limbic encephalitis: a prospective cohort study with development and validation of a diagnostic model.
    J Neurol. 2024 Jun 11. doi: 10.1007/s00415-024-12468.
    >> Share

  410. GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
    Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
    J Neurol. 2024 Jun 7. doi: 10.1007/s00415-024-12472.
    >> Share

  411. MUCK A, Pfeuffer S, Mir L, Genau S, et al
    Myasthenic crises are associated with negative long-term outcomes in myasthenia gravis.
    J Neurol. 2024 Jun 5. doi: 10.1007/s00415-024-12478.
    >> Share

  412. HERAUD C, Bresch S, Landes-Chateau C, Bourg V, et al
    Rituximab alone is as effective as associated with steroids on naive patients with generalized myasthenia gravis.
    J Neurol. 2024 Jun 5. doi: 10.1007/s00415-024-12454.
    >> Share

  413. STARK AJ, Mobley BC, Eaton JE
    Progressive leukoencephalopathy as a manifestation of primary angiitis of the central nervous system: case report and review of the literature.
    J Neurol. 2024;271:3648-3652.
    >> Share

    May 2024
  414. PORTACCIO E, Betti M, De Meo E, Addazio I, et al
    Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
    J Neurol. 2024 May 28. doi: 10.1007/s00415-024-12448.
    >> Share

  415. HUANG W, Zhang H, Li X, Zhang J, et al
    Prognostic factors underlying the development of drug-resistant epilepsy in patients with autoimmune encephalitis: a retrospective cohort study.
    J Neurol. 2024 May 27. doi: 10.1007/s00415-024-12432.
    >> Share

  416. CHAE J, Nguyen TT, Oh SY
    Quantification of saccadic fatigability and diagnostic efficacy for myasthenia gravis.
    J Neurol. 2024 May 26. doi: 10.1007/s00415-024-12461.
    >> Share

  417. MONTEIRO I, Nicolella V, Fiorenza M, Novarella F, et al
    The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
    J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434.
    >> Share

  418. FJORDSIDE L, Nissen MS, Florescu AM, Storgaard M, et al
    Validation of a risk score to differentiate autoimmune and viral encephalitis: a Nationwide Cohort Study in Denmark.
    J Neurol. 2024 May 18. doi: 10.1007/s00415-024-12392.
    >> Share

  419. CORTESE R, Battaglini M, Stromillo ML, Luchetti L, et al
    Regional hippocampal atrophy reflects memory impairment in patients with early relapsing remitting multiple sclerosis.
    J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12290.
    >> Share

  420. WOLF E, Wicklein R, Aly L, Schmaderer C, et al
    Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjogren's syndrome.
    J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12414.
    >> Share

  421. FREEDMAN DE, Oh J, Kiss A, Puopolo J, et al
    The influence of depression and anxiety on cognition in people with multiple sclerosis: a cross-sectional analysis.
    J Neurol. 2024 May 11. doi: 10.1007/s00415-024-12409.
    >> Share

  422. BARDEL B, Creange A, Bonardet N, Bapst B, et al
    Motor function in multiple sclerosis assessed by navigated transcranial magnetic stimulation mapping.
    J Neurol. 2024 May 6. doi: 10.1007/s00415-024-12398.
    >> Share

  423. GALPERIN I, Buzaglo D, Gazit E, Shimoni N, et al
    Gait and heart rate: do they measure trait or state physical fatigue in people with multiple sclerosis?
    J Neurol. 2024 May 2. doi: 10.1007/s00415-024-12339.
    >> Share

  424. PREZIOSA P, Rocca MA, Filippi M
    Radiologically isolated syndromes: to treat or not to treat?
    J Neurol. 2024;271:2370-2378.
    >> Share

  425. LEHNERER S, Herdick M, Stegherr R, Gerischer L, et al
    Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient's perspective.
    J Neurol. 2024;271:2824-2839.
    >> Share

  426. KONEN FF, Jendretzky KF, Ratuszny D, Schuppner R, et al
    Ravulizumab in myasthenic crisis: the first case report.
    J Neurol. 2024;271:2898-2901.
    >> Share

  427. BURTON JM, Youn S, Al-Ani A, Costello F, et al
    Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
    J Neurol. 2024;271:2662-2671.
    >> Share

  428. HEIDER D, Stetefeld H, Meisel A, Bosel J, et al
    POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic crisis.
    J Neurol. 2024;271:2875-2879.
    >> Share

  429. RISI M, Greco G, Masciocchi S, Rigoni E, et al
    MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment.
    J Neurol. 2024;271:2840-2843.
    >> Share

  430. DOUBROVINSKAJA S, Korporal-Kuhnke M, Jarius S, Haas J, et al
    Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
    J Neurol. 2024;271:2866-2870.
    >> Share

  431. ROCCA MA, Romano F, Tedone N, Filippi M, et al
    Advanced neuroimaging techniques to explore the effects of motor and cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2024 May 1. doi: 10.1007/s00415-024-12395.
    >> Share

    April 2024
  432. DIMAURO KA, Swetlik C, Cohen JA
    Management of multiple sclerosis in older adults: review of current evidence and future perspectives.
    J Neurol. 2024 Apr 30. doi: 10.1007/s00415-024-12384.
    >> Share

  433. ROSENSTEIN I, Nordin A, Sabir H, Malmestrom C, et al
    Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
    J Neurol. 2024 Apr 26. doi: 10.1007/s00415-024-12389.
    >> Share

  434. FONTE J, Stabile A, de Curtis M, Di Giacomo R, et al
    Seizures in autoimmune-associated epilepsy: a long-term video-EEG monitoring study.
    J Neurol. 2024 Apr 24. doi: 10.1007/s00415-024-12385.
    >> Share

  435. NAUTA IM, van Dam M, Bertens D, Kessels RPC, et al
    Improved quality of life and psychological symptoms following mindfulness and cognitive rehabilitation in multiple sclerosis and their mediating role for cognition: a randomized controlled trial.
    J Neurol. 2024 Apr 23. doi: 10.1007/s00415-024-12327.
    >> Share

  436. SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
    Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
    J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
    >> Share

  437. HIRT J, Dembowska K, Woelfle T, Axfors C, et al
    Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
    J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
    >> Share

  438. SINGER BA, Feng J, Chiong-Rivero H
    Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
    J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
    >> Share

  439. ZHANG Y, Liu D, Zhang Z, Huang X, et al
    Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
    J Neurol. 2024 Apr 11. doi: 10.1007/s00415-024-12367.
    >> Share

  440. STALTER J, Pars K, Witt K
    Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
    J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
    >> Share

  441. MARTINEZ-MARTINEZ L, Lacruz AC, Querol L, Cortes-Vicente E, et al
    Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12317.
    >> Share

  442. CELIK M, Baba C, Irmak C, Ozakbas S, et al
    Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
    >> Share

  443. STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
    Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
    >> Share

  444. TERAYAMA A, Kuwahara M, Yoshikawa K, Yamagishi Y, et al
    Takotsubo cardiomyopathy in Guillain-Barre syndrome.
    J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12295.
    >> Share

  445. MAIDA E, Moccia M, Palladino R, Borriello G, et al
    ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
    J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
    >> Share

  446. SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
    Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
    J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
    >> Share

  447. GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
    Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
    J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
    >> Share

  448. MCWILLIAM O, Gramkow MH, Blaabjerg M, Clemmensen FK, et al
    Differentiating anti-IgLON5 disease and Lewy body dementia: a systematic review.
    J Neurol. 2024;271:1707-1716.
    >> Share

  449. WANG Y, Hu C, Aljarallah S, Reyes Mantilla M, et al
    Expanding clinical profiles and prognostic markers in stiff person syndrome spectrum disorders.
    J Neurol. 2024;271:1861-1872.
    >> Share

  450. TEDONE N, Vizzino C, Meani A, Gallo A, et al
    The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
    J Neurol. 2024;271:1813-1823.
    >> Share

  451. GLASER A, Butzkueven H, van der Walt A, Gray O, et al
    Big Multiple Sclerosis Data network: an international registry research network.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
    >> Share

  452. HUA T, Fan H, Duan Y, Tian D, et al
    Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
    >> Share

    March 2024
  453. GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
    Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
    J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
    >> Share

  454. SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
    Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
    >> Share

  455. MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
    Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
    J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
    >> Share

  456. ZHANG H, Ma J, Feng Y, Ma H, et al
    Efgartigimod in the treatment of Guillain-Barre syndrome.
    J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12321.
    >> Share

  457. FUCHS L, Shelly S, Vigiser I, Kolb H, et al
    Real-World experience with efgartigimod in patients with myasthenia gravis.
    J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12293.
    >> Share

  458. PILOTTO S, Floris M, Solla P, Pugliatti M, et al
    Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
    J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
    >> Share

  459. LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
    Correction to: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
    J Neurol. 2024 Mar 23. doi: 10.1007/s00415-024-12238.
    >> Share

  460. GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
    Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
    J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
    >> Share

  461. ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
    Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
    J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
    >> Share

  462. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
    J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
    >> Share

  463. VILASECA A, Farina A, Villagran-Garcia M, Pegat A, et al
    Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
    J Neurol. 2024 Mar 11. doi: 10.1007/s00415-024-12252.
    >> Share

  464. KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
    The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
    >> Share

  465. HEGEN H, Berek K, Deisenhammer F, Berger T, et al
    Sex impacts treatment decisions in multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
    >> Share

  466. HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
    Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
    >> Share

  467. ZID Y, Robertson NP
    Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
    J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
    >> Share

  468. LI J, Wu X, Chu T, Tan X, et al
    The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
    J Neurol. 2024 Mar 3. doi: 10.1007/s00415-024-12247.
    >> Share

  469. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
    >> Share

    February 2024
  470. SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
    Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
    J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
    >> Share

  471. TOLJAN K, Briggs FBS
    Male sexual and reproductive health in multiple sclerosis: a scoping review.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
    >> Share

  472. LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
    A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
    >> Share

  473. VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
    Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
    J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
    >> Share

  474. NGUYEN TT, Chae J, Kang JJ, Oh SY, et al
    Saccadic fatigue as an early indicator for diagnosing myasthenia gravis.
    J Neurol. 2024 Feb 25. doi: 10.1007/s00415-024-12262.
    >> Share

  475. WEISS MD, Freimer M, Leite MI, Maniaol A, et al
    Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
    J Neurol. 2024 Feb 24. doi: 10.1007/s00415-024-12209.
    >> Share

  476. OHNARI K, Hashimoto T, Iwanaka Y, Ohnari K, et al
    Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.
    J Neurol. 2024 Feb 23. doi: 10.1007/s00415-024-12245.
    >> Share

  477. GREGULETZ P, Plotz M, Baade-Buttner C, Bien CG, et al
    Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12224.
    >> Share

  478. CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
    Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
    >> Share

  479. BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
    The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
    J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
    >> Share

  480. HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
    Prodromal multiple sclerosis: considerations and future utility.
    J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
    >> Share

  481. VANCURA J, Boyd NK, Vogel BN, Nagesh D, et al
    Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutieres syndrome.
    J Neurol. 2024;271:1019-1022.
    >> Share

    January 2024
  482. BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
    Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
    >> Share

  483. BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
    Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
    >> Share

  484. NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
    Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
    J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
    >> Share

  485. CENSI S, Bisaccia G, Gallina S, Tomassini V, et al
    Guillain-Barre syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
    J Neurol. 2024 Jan 17. doi: 10.1007/s00415-024-12186.
    >> Share

  486. FENG G, Posa S, Sureshkumar A, Simpson S, et al
    Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
    J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
    >> Share

  487. ZHENG P, Sandroff BM, Motl RW
    Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
    J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
    >> Share

  488. MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
    Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
    J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
    >> Share

  489. TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
    Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
    J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
    >> Share

  490. LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
    Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
    J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
    >> Share

  491. FAVRUZZO F, Palmieri A, Giopato F, Cardellini D, et al
    Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and Varicella-Zoster virus infections: a case report.
    J Neurol. 2024;271:75-78.
    >> Share

  492. NEUMANN B, Angstwurm K, Dohmen C, Mergenthaler P, et al
    Weaning and extubation failure in myasthenic crisis: a multicenter analysis.
    J Neurol. 2024;271:564-574.
    >> Share

  493. WIESENFARTH M, Stamminger T, Zizer E, Tumani H, et al
    Neurological manifestation of HEV infection: still a rare disease entity?
    J Neurol. 2024;271:386-394.
    >> Share

  494. MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
    Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
    J Neurol. 2024;271:374-385.
    >> Share

  495. KUMPFEL T, Giglhuber K, Aktas O, Ayzenberg I, et al
    Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
    J Neurol. 2024;271:141-176.
    >> Share

    December 2023
  496. AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
    Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
    J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
    >> Share

  497. LIU M, Ren H, Wang L, Fan S, et al
    Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.
    J Neurol. 2023 Dec 23. doi: 10.1007/s00415-023-12128.
    >> Share

  498. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
    >> Share

  499. ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
    Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
    >> Share

  500. MISTRI D, Valsasina P, Storelli L, Filippi M, et al
    Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
    J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
    >> Share

  501. HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
    Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
    J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
    >> Share

  502. COVEY TJ, Golan D, Sergott R, Wilken J, et al
    Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
    J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
    >> Share

  503. ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
    Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
    >> Share

  504. TSAI CC, Jette S, Tremlett H
    Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
    J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
    >> Share

  505. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
    J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
    >> Share

    November 2023
  506. MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
    Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
    J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
    >> Share

  507. MISTRI D, Tedone N, Biondi D, Vizzino C, et al
    Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
    J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
    >> Share

  508. JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
    Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
    >> Share

  509. BISECCO A, Matrone F, Capobianco M, De Luca G, et al
    COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
    >> Share

  510. SUN Y, Li G, Liu X, Zhao X, et al
    Cerebral glucose hypometabolism and hypoperfusion of cingulate gyrus: an imaging biomarker of autoimmune encephalitis with psychiatric symptoms.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12051.
    >> Share

  511. KENNEDY PGE, George W, Yu X
    The elusive nature of the oligoclonal bands in multiple sclerosis.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
    >> Share

  512. DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
    SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
    J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
    >> Share

  513. FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
    Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
    J Neurol. 2023;270:5392-5397.
    >> Share

  514. JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
    Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
    J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
    >> Share

  515. GENG C, Zhao W, Wang Z, Wu J, et al
    Acute necrotizing encephalopathy associated with COVID-19: case series and systematic review.
    J Neurol. 2023;270:5171-5181.
    >> Share

  516. QIN M, Chen J, Guo X, Xiang X, et al
    Movement disorders in autoimmune encephalitis: an update.
    J Neurol. 2023;270:5288-5302.
    >> Share

    October 2023
  517. MANTERO V, Cordano C, Balgera R, Basilico P, et al
    Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
    >> Share

  518. KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
    Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
    >> Share

  519. DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
    Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
    >> Share

  520. RIVEL M, Achiron A, Stern Y, Zeilig G, et al
    Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
    J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
    >> Share

  521. ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
    Identification and management of subclinical disease activity in early multiple sclerosis: a review.
    J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
    >> Share

  522. ZINGANELL A, Gobel G, Berek K, Hofer B, et al
    Multiple sclerosis in the elderly: a retrospective cohort study.
    J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
    >> Share

  523. SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
    Multiple sclerosis: time for early treatment with high-efficacy drugs.
    J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
    >> Share

  524. RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
    Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
    >> Share

  525. MANZANO GS, McEntire C, Venna N
    Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-11992.
    >> Share

  526. ZHANG Z, Wang Z, Du X, Huang X, et al
    Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
    J Neurol. 2023 Oct 7. doi: 10.1007/s00415-023-12036.
    >> Share

  527. KRAKER JA, Chen JJ
    An update on optic neuritis.
    J Neurol. 2023;270:5113-5126.
    >> Share

  528. BRISCA G, Marini C, Buratti S, Mariani M, et al
    Acute pediatric encephalitis: etiology, course, and outcome of a 12-year single-center immunocompetent cohort.
    J Neurol. 2023;270:5034-5047.
    >> Share

  529. WANG R, Sun D, Du Q, Shi Z, et al
    Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
    J Neurol. 2023;270:5085-5089.
    >> Share

    September 2023
  530. RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
    Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
    >> Share

  531. LI Y, Saul A, Taylor B, Ponsonby AL, et al
    Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
    J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
    >> Share

  532. KERNER C, Kotobelli K, Appleby BS, Cohen ML, et al
    Pathological findings in autoimmune encephalitis autopsy specimens from cases of suspected prion disease.
    J Neurol. 2023 Sep 27. doi: 10.1007/s00415-023-12003.
    >> Share

  533. WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
    Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
    >> Share

  534. FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
    Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
    J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
    >> Share

  535. GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
    Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.
    J Neurol. 2023 Sep 14. doi: 10.1007/s00415-023-11967.
    >> Share

  536. MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
    Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
    J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
    >> Share

  537. DI STEFANO V, Alonge P, Rini N, Militello M, et al
    Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
    J Neurol. 2023 Sep 8. doi: 10.1007/s00415-023-11970.
    >> Share

  538. JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
    Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
    J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
    >> Share

    August 2023
  539. BONACCHI R, Valsasina P, Pagani E, Meani A, et al
    Sex-related differences in upper limb motor function in healthy subjects and multiple sclerosis patients: a multiparametric MRI study.
    J Neurol. 2023 Aug 28. doi: 10.1007/s00415-023-11948.
    >> Share

  540. JAKIMOVSKI D, Zivadinov R, Weinstock Z, Fuchs TA, et al
    Cortical thickness and cognition in older people with multiple sclerosis.
    J Neurol. 2023 Aug 27. doi: 10.1007/s00415-023-11945.
    >> Share

    July 2023
  541. PETROU P, Achiron A, Cohen EG, Garty M, et al
    Practical recommendations on treatment of multiple sclerosis with Cladribine: an Israeli Experts Group‏ Viewpoint.
    J Neurol. 2023 Jul 12. doi: 10.1007/s00415-023-11846.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016